Ruprecht-karls-universitat Heidelberg

Metanomics Gmbh

Universitat Heidelberg

Deutsches Krebsforschungszentrum

Ruprecht-karls-universitaet Heidelberg

Universitat Ulm

Hummingbird Diagnostics Gmbh

Comprehensive Biomarker Center Gmbh

Universitatsklinikum Heidelberg

Rupreht-karls-universität Heidelberg

Baysal-temel, Ezgi

Katus, Hugo

Lehmann, Lorenz

Backs, Johannes

Mathe.medical Gmbh

Hugo Katus

Jens Fuhrmann

Regina Reszka

Patrick Most

Benjamin Meder

Norbert Frey

Tanja Weis

Oliver Müller

Markus Beier

Andreas Keller

Edgar Leibold

Kristina Busch

Jürgen Kastler

Zegeye Jebessa

Andrew Remppis

Mirko Voelkers

Wolfgang Rottbauer

Johannes Backs

Johanna Wolf

Lorenz Lehmann

Peer Friedrich Stähler

Martin Kluttig

Bianca Bethan

Jürgen Kleinschmidt

Oliver Mueller

Pessah Yampolsky

Anca Remes

Markus Hecker

Andreas Wagner

Andreas Jungmann

Britta Vogel

Karl Varadi

Oliver Zimmermann

Ziya Kaya

Juergen Kastler

Johanna Sigl

Jan Haas

Dierk Thomas

Patrick A Schweizer

Michael Koenen

Jan Torzewski

Ezgi Baysal

Christian Oeing

Christian Volz

Michaela SCHÄFER

Stephan Herzig

Johanna Sigl Geb Wolf

Peer Stähler

Sebastian Sager

Eberhard Scholz

Constanze Schmidt

Philipp Schlegel

Nuttarak Sasipong

Stefan Kallenberger

The present invention relates to a polynucleotide comprising a Nuclear factor of activated T-cells (NFAT) binding site sequence and a reverse complement of said NFAT binding site sequence separated by a spacer sequence, to said polynucleotide for use in treating and/or preventing disease, and to viral particles, compositions, and uses related thereto. The present invention further relates to a polynucleotide comprising a Nuclear factor of activated T-cells (NFAT) binding site sequence and a reverse complement of said NFAT binding site sequence for use in treating and/or preventing an NFAT-mediated disease.

NFAT binding polynucleotides

The present invention relates to Abhydrolase containing domain 5 (ABHD5) and N-terminal fragments of HDAC4 (HDAC4-NT) and variants of the aforementioned peptides for the treatment and prevention of heart failure. The present invention further provides vectors for the cardiomyocyte-specific expression of said peptides and a test system comprising ABHD5 for the identification of novel compounds which are useful for the treatment of heart failure.

ABHD5 and partial HDAC4 fragments and variants as a therapeutic approach for the treatment of cardiovascular diseases

The present invention relates to S100 protein and nuclei acids encoding S100 protein for enhancing the cardiac power as well as vectors and pharmaceuticals comprising the same and uses thereof.

S100 based treatment of cardiac power failure

The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of dilated cardiomyopathy in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of dilated cardiomyopathy in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of dilated cardiomyopathy in a body fluid sample from a subject.

Complex sets of miRNAs as non-invasive biomarkers for dilated cardiomyopathy

The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject and a method for monitoring progression or regression of heart failure in a subject. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

Means and methods for diagnosing and monitoring heart failure in a subject

The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject, a method for identifying whether a subject is in need for a therapy of heart failure or a method for determining whether a heart failure therapy is successful. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

Means and methods for diagnosing heart failure in a subject

The present invention relates to an in vitro method for evaluating the anti- or pro-arrhythmic potential, cardiotoxicity and/or modulation capacity of cardiomyocyte function of compound(s). The present invention also relates to compound(s) identified or evaluated in the method of the invention for use in the treatment of a heart disease. The present invention further relates to the use of the density change of cardiac Nav 1.5 sodium channels in intercalated discs of cardiomyocytes as marker and/or diagnostic for the anti- or pro-arrhythmic potential of a compound, the cardiotoxicity of a compound or modulation capacity of cardiomyocyte function by said compound, and/or in preclinical assessment for cardiac liability of compounds and cardio-safety assessment. The present invention further relates to a kit for evaluating the anti- or pro-arrhythmic potential, cardiotoxicity and/or modulation capacity of cardiomyocyte function of compound(s).

Method and kit for assessment of sodium channel-related anti- or pro-arrhythmic potential of compounds

The present invention relates to the use of DNA methylation profiles of patient samples for the diagnosis, prognosis and/or therapy monitoring of a heart disease in a patient, wherein the DNA methylation profile of the patient sample is compared with the DNA methylation profile of a control sample, and wherein a difference in the DNA methylation profile of the patient sample compared to the control sample is indicative of a heart disease or of the risk for developing a heart disease or for a prediction of therapy effects or therapy outcome. The present invention further relates to methods for the diagnosis, prognosis and/or therapy monitoring of a heart disease in a patient, comprising determining the DNA methylation profile in a patient sample comprising genomic DNA from heart cells, heart tissue or peripheral blood; and comparing the DNA methylation profile in the patient sample with the DNA methylation profile from a normal subject not having a heart disease or having a normal heart function. The present invention furthermore relates to kits that are suitable for the methods and uses of the invention. The present invention furthermore relates to the use of ADORA2A, ERBB3, LY75, HOXB13, GF11, CLDN4, FDX1, ID4, NAT1, PPARGC1A, SULF2, TFF1, TKT, ATP2C, CCDC59, GSTM5m, SLC9A6 and TDG as marker for the diagnosis, prognosis and/or therapy monitoring of a heart disease in a patient.

Epigenetic signatures as marker for cardiomyopathies and myocardial insufficiencies

The present invention relates to single polynucleotides or sets of polynucleotides for detecting single miRNAs or sets of miRNAs for diagnosing and/or prognosing of an acute coronary syndrome in a blood sample from a human. Further, the present invention relates to means for diagnosing and/or prognosing of an acute coronary syndrome comprising said polynucleotides or sets of polynucleotides. Furthermore, the present invention relates to a method for diagnosing and/or prognosing of an acute coronary syndrome based on the determination of expression profiles of single miRNAs or sets of miRNAs representative for an acute coronary syndrome compared to a reference. In addition, the present invention relates to a kit for diagnosing and/or prognosing of an acute coronary syndrome comprising means for determining expression profiles of single miRNAs or sets of miRNAs representative for an acute coronary syndrome and at least one reference.

Complex miRNA sets as novel biomarkers for an acute coronary syndrome

The present invention relates to shortened peptides comprising a muscle function enhancing amino acid sequence which is derived from the S100 calcium binding protein family. Furthermore, the present invention provides said peptides for medical use, in particular, for treating or preventing disorders associated with muscular malfunction, such as skeletal muscle or cardiac muscle disorders. The present invention also provides a pharmaceutical compositions comprising said peptides and a method for treating or preventing disorders associated with muscular malfunction using said peptides or said pharmaceutical compositions.

Short peptides for enhancing muscle function

The present invention relates to a peptide comprising a muscle function enhancing amino acid sequence which is derived from the S100 calcium binding protein family. Furthermore, the present invention provides said peptide for medical use, in particular, for treating or preventing disorders associated with muscular malfunction, such as skeletal muscle or cardiac muscle disorders. The present invention also provides a pharmaceutical composition comprising said peptide and a method for treating or preventing disorders associated with muscular malfunction using said peptide or said pharmaceutical composition.

Muscle function enhancing peptide

The present invention relates to the field of cell-based therapeutics. Specifically, the invention is concerned with a composition comprising a macrophage overexpressing interleukin 10 (IL-10) from transfected IL-10 encoding mRNA for use as a medicament. Moreover, a method for manufacturing a medicament for treating and/or preventing inflammation or a disease or disorder associated therewith comprising the steps of obtaining a macrophage from a sample of said subject, transfecting mRNA encoding IL-10 into said macrophage, and formulating said macrophage in a composition suitable for administration to the said subject, whereby the medicament is manufactured. Finally, a kit is provided for manufacturing such a medicament.

Use of interleukin 10 mRNA transfected macrophages in anti-inflammatory therapies

The present invention is concerned with the provision of a polynucleotide encoding an AAV capsid polypeptide comprising an inserted peptide and a vector comprising said polynucleotide. Moreover, contemplated is a host cell comprising said polynucleotide or vector, a method for the manufacture of said capsid polypeptide as well as said polypeptide. Further included is an antibody specifically binding to said polypeptide and a medicament comprising said polynucleotide, vector, polypeptide, or antibody. Also contemplated are the use of said polynucleotide, vector, polypeptide, or antibody for the manufacture of a medicament for the treatment of vascular disease and a method for the identification of a compound binding to said polypeptide.

Modified AAV capsid polypeptides

Growing community of inventors

Heidelberg, Germany

Hugo Katus